HomepageD4S • FRA
add
Daiichi Sankyo
Vorige slotkoers
€ 30,00
Dag-range
€ 30,00 - € 30,00
Jaar-range
€ 23,81 - € 37,90
Beurswaarde
63,68Â mld. USD
Gem. volume
52,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
TYO
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(JPY) | jun 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 436,18Â mld. | 24,32% |
Bedrijfskosten | 248,15Â mld. | 16,43% |
Netto inkomsten | 85,38Â mld. | 49,76% |
Netto winstmarge | 19,58 | 20,49% |
Winst per aandeel | — | — |
EBITDA | 109,60Â mld. | 88,30% |
Effectief belastingtarief | 22,52% | — |
Balans
Totale activa
Totale passiva
(JPY) | jun 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 805,26Â mld. | 54,96% |
Totale activa | 3,44Â bln. | 31,39% |
Totale passiva | 1,72Â bln. | 58,01% |
Totaal aandelenvermogen | 1,72 bln. | — |
Uitstaande aandelen | 1,91 mld. | — |
Koers-boekwaardeverhouding | 0,03 | — |
Rendement op activa | 6,74% | — |
Rendement op kapitaal | 12,87% | — |
Kasstroom
Nettomutatie in liquide middelen
(JPY) | jun 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 85,38Â mld. | 49,76% |
Operationele kasstroom | -110,04Â mld. | -137,99% |
Kasstroom uit beleggingen | 357,30Â mld. | 154,50% |
Kasstroom uit financiering | -107,56Â mld. | -230,66% |
Nettomutatie in liquide middelen | 158,08Â mld. | 103,34% |
Vrije kasstroom | 251,00Â mld. | 158,90% |
Over
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
CEO
Opgericht
28 sep 2005
Hoofdvestiging
Website
Werknemers
18.726